SB1711 establishes a temporary obesity treatment study committee within Arizona to examine whether the state’s Medicaid program, AHCCCS, should cover comprehensive treatment for people living with obesity. The committee is directed to study the cost, potential savings, effectiveness, health outcomes, and overall value of expanding coverage, and to identify additional public health resources or policy initiatives that could improve outcomes and reduce costs.
The committee is bipartisan and includes legislators, AHCCCS and Department of Health Services leadership or designees, patient advocacy representatives, physicians or medical society representatives, and a registered dietitian. It must meet at the call of the cochairpersons, does not receive compensation beyond expense reimbursement, and must submit a report with findings and recommendations by December 31, 2025. The statutory section is set to repeal on September 30, 2026, making the committee temporary.
Impact
The bill does not immediately change AHCCCS benefit coverage or mandate obesity treatment services; instead, it creates a short-lived study committee to evaluate possible future policy changes. Its main legal effect is to add a new temporary section to Arizona law directing state officials and stakeholders to produce a report that could inform later administrative or legislative action on Medicaid coverage for obesity treatment.
Sentiment
The bill appears to have received generally favorable, though not unanimous, support. It passed the Senate and House with comfortable margins and advanced through health committees with positive recommendations, suggesting broad interest in studying obesity treatment coverage and its fiscal and public health implications. The presence of some no votes in both chambers indicates that while the concept was acceptable to many lawmakers, it was not entirely without reservation.
Contention
The main point of contention is likely the policy question underlying the study: whether AHCCCS should expand coverage for comprehensive obesity treatment and what that could cost the state versus what savings or health benefits it might produce. Supporters appear to favor a data-driven review involving medical, patient advocacy, and state agency perspectives, while opponents may have concerns about Medicaid expansion of benefits, budget impacts, or the precedent of covering obesity treatment as a comprehensive service. The recorded votes show some opposition in committee and on final passage, but no specific transcript objections were provided.
Enacting the right to try for individualized treatments act to permit a manufacturer to make an individualized investigative treatment available to a requesting patient.
Health care; creating the Right to Try for Individualized Treatments Act; authorizing individualized investigational treatments for eligible patients. Effective date.